GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MedMen Enterprises Inc (OTCPK:MMNFQ) » Definitions » EBITDA

MMNFQ (MedMen Enterprises) EBITDA : $-119.1 Mil (TTM As of Mar. 2023)


View and export this data going back to 2018. Start your Free Trial

What is MedMen Enterprises EBITDA?

MedMen Enterprises's EBITDA for the three months ended in Mar. 2023 was $-21.7 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-119.1 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

MedMen Enterprises's EBITDA per Share for the three months ended in Mar. 2023 was $-0.02. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


MedMen Enterprises EBITDA Historical Data

The historical data trend for MedMen Enterprises's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMen Enterprises EBITDA Chart

MedMen Enterprises Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -88.58 -218.66 -418.06 -41.27 -106.73

MedMen Enterprises Quarterly Data
Apr18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.80 -95.68 -2.46 0.71 -21.71

Competitive Comparison of MedMen Enterprises's EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, MedMen Enterprises's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMen Enterprises's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MedMen Enterprises's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MedMen Enterprises's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

MedMen Enterprises's EBITDA for the fiscal year that ended in Jun. 2022 is calculated as

MedMen Enterprises's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Jun. 2022, MedMen Enterprises's EBITDA was $-106.7 Mil.

MedMen Enterprises's EBITDA for the quarter that ended in Mar. 2023 is calculated as

MedMen Enterprises's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2023, MedMen Enterprises's EBITDA was $-21.7 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-119.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

MedMen Enterprises  (OTCPK:MMNFQ) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


MedMen Enterprises EBITDA Related Terms

Thank you for viewing the detailed overview of MedMen Enterprises's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMen Enterprises Business Description

Traded in Other Exchanges
N/A
Address
10115 Jefferson Boulevard, Culver City, CA, USA, 90232
MedMen Enterprises Inc formerly known as Ladera Ventures Corp is the preeminent cannabis company with multiple assets and operations in California, Nevada, and New York, which combined account for nearly half of North America's addressable legal market. The company owns and operates licensed cannabis facilities in cultivation, manufacturing, and retail.

MedMen Enterprises Headlines

From GuruFocus

MedMen Announces Management and Board Changes

By Business Wire 01-24-2024

Q2 2020 Medmen Enterprises Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2021 Medmen Enterprises Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2022 Medmen Enterprises Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2020 Medmen Enterprises Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

MedMen Completes Sale of Florida Assets

By Business Wire Business Wire 08-22-2022

Q4 2021 Medmen Enterprises Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2020 Medmen Enterprises Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024